Αρχική Uncategorized Women at High Risk of Breast Cancer Find it Hard to Afford...

Women at High Risk of Breast Cancer Find it Hard to Afford Health Care Despite Insurance

Roughly three in ten uninsured Americans say they’ve gone without needed healthcare in the past year. While that may not be surprising, can issues like this face people with insurance, as well? A new study says they might.

Researchers from The Ohio State University interviewed 50 women at high risk of developing breast cancer and found that even those who were insured faced financial barriers to care. The findings were published in the Journal of Genetic Counseling.

PHOTO: ADOBE STOCK/WAVEBREAKMEDIAMICRO

Tasleem Padamsee, co-lead author and assistant professor of health services management and policy at Ohio State, says, “Financial barriers seem to regularly impede access to critical information that high-risk women can only get through genetic counseling and testing, and keep them from using regular screenings that could catch cancers in the earliest and most treatable stages.”

She added that cost barriers can also make it very difficult to access preventative measures and medications.

Researchers say that regardless of income level or coverage, the participants reported worries about the financial fallout of preventative measures. They often said they avoided doing things they didn’t think they could afford. However, this didn’t just include the cost of the actual procedures. Existing medical debt, bills to treat other illnesses in themselves or the family, and child care were also involved in the decision.

Another problem that was often reported was the lack of price transparency from insurance companies, leading women to guess what is covered and what isn’t.

PHOTO: ADOBE STOCK/WAVEBREAK3

There was another insurance-related barrier, as well.

Rachel Meadows, co-lead author who worked on the research as a doctoral student at Ohio State’s College of Public Health, explains, “Underinsurance was a really big factor – even for those women who have private insurance, they come across a lot of hurdles with requesting coverage for genetic testing, counseling, risk-reducing surgeries and enhanced breast screening.”

Meadows adds that many women were also concerned that they could face future discrimination if they have genetic testing, despite current laws prohibiting genetic discrimination.

Article continues below

Our Featured Programs

See how we’re making a difference for People, Pets, and the Planet and how you can get involved!

Padamsee says their findings show that high-risk patients may need providers who are prepared to share information on costs, coverage, and financial assistance programs. The study also sheds light on the need for insurance companies to be more transparent on full benefits and co-pays in ways people can understand.

Padamsee feels these important steps could lead to better outcomes for high-risk women, explaining, “These changes could improve women’s ability to access high-risk care, reduce the number and severity of future cancers, and avoid future cancer treatment costs for both patients and payers.”

PHOTO: ADOBE STOCK/WAVEBREAKMEDIAMICRO

The cost of care even with insurance isn’t just an issue to this group of women. According to KFF, about a third of insured Americans say it is difficult to afford their deductibles.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Foodie Friday: It’s Berry Season!

July is National Berry Month! If berries aren’t part of your daily diet, now is the perfect time to start eating more of these...

No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia

On 23 July 2021, the European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) has endorsed findings of...

Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home

A woman was 9 months pregnant when she found a pregnant stray cat. Unable to bear the thought of the fellow mom giving birth...

3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout

Karen Warner Schueler is the president of her own executive coaching firm and author of The Sudden Caregiver: A Roadmap for Resilient Caregiving. For...

FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL

July 29, 2021, by NCI Staff FDA's approval of Rylaze is expected to help address a long-running shortage of the drug Erwinia asparaginase for kids...

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib

On 22 July 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...